title: Effect of apolipoprotein E genotypes on the efficacy of ezetimibe monotherapy in patients with statin induced adverse effects.
abstract: OBJECTIVE
  The aim of this study was to clarify the effect of Apolipoprotein E (ApoE) polymorphism on the efficacy of cholesterol absorption inhibitor ezetimibe monotherapy on lipid parameters.
  
  
  METHODS
  63 hyperlipidemic patients with statin induced adverse effects were involved in the study. We examined the effect of 10 mg/day ezetimibe treatment on lipid levels after 3, 6 and 12 months of treatment in patients on a diet of only different ApoE genotypes.
  
  
  RESULTS
  Three months of ezetimibe treatment significantly decreased the total cholesterol (TC) (-10.1%), low-density lipoprotein (LDL-C) (-12.0%) (p < 0.001) and triglyceride (Tg) (-8%) levels (p < 0.05). After 6 and 12 months of treatment reduction in TC, LDL-C and Tg levels were even more pronounced. The genotype distribution of the patients were 2/2: 4.8%, 2/3: 7.9%, 3/3: 68.3%, 3/4: 19.0%. There were no patients with 2/4 and 4/4 genotypes. In patients with 2/3, 3/3 or 3/4 genotype, the ezetimibe treatment tended to be more effective on TC and LDL-C levels than in the 2/2 group, and the efficacy of ezetimibe on Tg levels were slightly better in 2/2 carriers compared to other patients.
  
  
  CONCLUSIONS
  The ApoE genotype does not predict the efficacy of ezetimibe treatment on serum lipid parameters.
authors.forename: Mariann
authors.initials: M
authors.lastname: Harangi
authors.forename: Ildikó
authors.initials: I
authors.lastname: Seres
authors.forename: István
authors.initials: I
authors.lastname: Balogh
authors.forename: Tamás
authors.initials: T
authors.lastname: Köbling
authors.forename: János
authors.initials: J
authors.lastname: Harangi
authors.forename: József
authors.initials: J
authors.lastname: Varga
authors.forename: László
authors.initials: L
authors.lastname: Márk
authors.forename: György
authors.initials: G
authors.lastname: Paragh
mesh_terms: D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001057:Apolipoproteins E / Q000235:genetics*; D001384:Azetidines / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D000069438:Ezetimibe; D005260:Female; D005838:Genotype; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D001057:Apolipoproteins E; D001384:Azetidines; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014280:Triglycerides; D002784:Cholesterol; D000069438:Ezetimibe